Optimisation of the dosing regimen of trimethoprim/sulfamethoxazole in septic patients on CRRT based on the PPK-PD-PG model

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400088397

Enrollment

Unknown

Registered

2024-08-19

Start date

2024-08-30

Completion date

Unknown

Last updated

2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

sepsis

Interventions

Treatment group: Treatmenteive standard dose of trimethoprim/sulfamethoxazole:None

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) Empirical or targeted anti-infective therapy with cotrimoxazole in septic patients receiving CRRT; (2) Administration of trimethoprim/sulfamethoxazole for >3 d; (3) Adult patients =18 years of age; (4) Patients agreed and signed an informed consent form; (5) Patients had continuous blood concentration monitoring data during the study period.

Exclusion criteria

Exclusion criteria: (1) Suffering from serious complications such as severe cardiac, hepatic, and renal diseases that may affect drug metabolism; (2) Pregnant women; (3) Patients with incomplete or unreliable blood concentration data during the study period; patients not receiving CRRT during the study period

Design outcomes

Primary

Measure	Time frame
Blood concentration;Drug clearance;	—

Secondary

Measure	Time frame
Healing conditions;	—

Countries

China

Contacts

Public ContactMin Wang

Hainan Provincial People 's Hospital

wangmin2020@hainmc.edu.cn+86 157 9907 7523

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026